Who is sponsoring NCT03958409?

NCT03958409 is sponsored by Yale University.

What drugs are being tested in NCT03958409?

Interventions in NCT03958409: measurements to evaluate metabolic bone disease, standard care.

What condition does NCT03958409 study?

NCT03958409 studies Skeletal Anomalies, Kidney Transplant; Complications.

Is NCT03958409 still recruiting?

NCT03958409 is currently completed. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT03958409

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

Completed NA Last updated 28 February 2023

What this trial tests

NA trial testing measurements to evaluate metabolic bone disease in Skeletal Anomalies in 8 participants. Completed in 2 December 2021.

Timeline

12 December 2018

Primary endpoint
2 December 2021

2 December 2021

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	8
Start date	12 December 2018
Primary completion	2 December 2021
Estimated completion	2 December 2021
Sites	1 location across United States

Drugs / interventions tested

measurements to evaluate metabolic bone disease
standard care — full drug profile →

Conditions studied

Skeletal Anomalies — all drugs for Skeletal Anomalies →
Kidney Transplant; Complications — all drugs for Kidney Transplant; Complications →

Sponsor

Yale University

Who can join

Adults 30 to 65, any sex, with Skeletal Anomalies or Kidney Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is a well-documented increased risk for disordered mineral bone homeostasis in Kidney Transplant Recipients (KTRs) when compared to the general population, leading to a markedly increased risk for fragility fractures and their associated morbidity and mortality. A more uniform and rigorous evaluation of bone and mineral homeostasis,than is afforded to patients under "normal care", will result in better clinical outcomes in KTRs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03958409 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03958409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing